$2.76 Billion is the total value of Tekla Capital Management LLC's 212 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 13.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GILD | Sell | Gilead Sciences, Inc. | $149,966,000 | +2.6% | 1,942,317 | -5.9% | 5.44% | -2.0% |
| AMGN | Sell | Amgen Inc. | $140,513,000 | +8.7% | 677,855 | -3.2% | 5.10% | +3.9% |
| BIIB | Sell | Biogen Inc. | $138,286,000 | +17.9% | 391,402 | -3.1% | 5.02% | +12.7% |
| UNH | Sell | Unitedhealth Group Incorporated | $91,647,000 | -12.2% | 344,486 | -19.0% | 3.32% | -16.1% |
| ILMN | Sell | Illumina, Inc. | $89,092,000 | +12.1% | 242,717 | -14.7% | 3.23% | +7.2% |
| VRTX | Sell | Vertex Pharmaceuticals Incorporated | $78,683,000 | -20.4% | 408,235 | -29.8% | 2.85% | -23.9% |
| PFE | Sell | Pfizer Inc. | $59,675,000 | -30.3% | 1,354,093 | -42.6% | 2.16% | -33.4% |
| ABBV | Sell | AbbVie Inc. | $46,541,000 | -2.2% | 492,078 | -4.2% | 1.69% | -6.5% |
| MRK | Sell | Merck & Co., Inc. | $45,771,000 | -41.3% | 645,208 | -49.8% | 1.66% | -43.9% |
| SRPT | Sell | Sarepta Therapeutics, Inc. | $36,046,000 | +16.3% | 223,182 | -4.8% | 1.31% | +11.1% |
| MDT | Sell | Medtronic plcshares | $33,391,000 | -7.9% | 339,439 | -19.9% | 1.21% | -12.0% |
| ABT | Sell | Abbott Laboratories | $28,737,000 | -24.9% | 391,719 | -37.5% | 1.04% | -28.2% |
| AZN | Sell | AstraZeneca PLCsponsored adr | $28,436,000 | +4.0% | 718,624 | -7.7% | 1.03% | -0.7% |
| NBIX | Sell | Neurocrine Biosciences, Inc. | $26,143,000 | -1.4% | 212,630 | -21.2% | 0.95% | -5.8% |
| IDXX | Sell | IDEXX Laboratories, Inc. | $25,566,000 | -9.5% | 102,403 | -21.0% | 0.93% | -13.5% |
| CNC | Sell | Centene Corporation | $24,159,000 | +6.1% | 166,869 | -9.7% | 0.88% | +1.4% |
| LLY | Sell | Eli Lilly and Company | $23,226,000 | -30.2% | 216,442 | -44.5% | 0.84% | -33.3% |
| HUM | Sell | Humana Inc. | $23,184,000 | -25.9% | 68,487 | -34.8% | 0.84% | -29.1% |
| BMY | Sell | Bristol-Myers Squibb Company | $22,725,000 | -36.9% | 366,064 | -43.8% | 0.82% | -39.7% |
| TEVA | Sell | Teva Pharmaceutical Industries Limitedsponsored adr | $20,096,000 | -23.8% | 932,948 | -13.9% | 0.73% | -27.1% |
| ENDP | Sell | Endo International plcshares | $17,151,000 | +68.7% | 1,019,048 | -5.5% | 0.62% | +61.1% |
| BSX | Sell | Boston Scientific Corporation | $17,132,000 | +14.5% | 444,991 | -2.8% | 0.62% | +9.3% |
| AET | Sell | Aetna Inc. | $16,966,000 | -4.8% | 83,637 | -13.9% | 0.62% | -9.0% |
| XBI | Sell | SPDR S&P Biotech ETFs&p biotech etf | $12,367,000 | -48.1% | 129,000 | -48.5% | 0.45% | -50.4% |
| ALNY | Sell | Alnylam Pharmaceuticals, Inc. | $11,043,000 | -14.0% | 126,176 | -3.2% | 0.40% | -17.9% |
| MCK | Sell | McKesson Corporation | $11,003,000 | -16.5% | 82,947 | -16.0% | 0.40% | -20.2% |
| HCA | Sell | HCA Healthcare, Inc. | $10,341,000 | +34.2% | 74,335 | -1.0% | 0.38% | +28.4% |
| GSK | Sell | GlaxoSmithKline plcshares | $8,785,000 | -39.3% | 218,700 | -39.1% | 0.32% | -41.9% |
| CLLS | Sell | Cellectis SAsponsored adr | $7,873,000 | -12.5% | 278,988 | -12.3% | 0.29% | -16.1% |
| GWPH | Sell | GW Pharmaceuticals plcads | $7,531,000 | -24.5% | 43,598 | -39.0% | 0.27% | -28.0% |
| MPW | Sell | Medical Properties Trust, Inc. | $7,118,000 | -41.0% | 477,409 | -44.4% | 0.26% | -43.5% |
| ESRX | Sell | Express Scripts Holding Company | $5,059,000 | -38.5% | 53,250 | -50.0% | 0.18% | -41.3% |
| MDCO | Sell | The Medicines Company | $4,960,000 | -43.4% | 165,841 | -30.5% | 0.18% | -45.8% |
| ADAP | Sell | Adaptimmune Therapeutics plcsponsored adr | $4,768,000 | -53.0% | 351,618 | -58.9% | 0.17% | -55.1% |
| MASI | Sell | Masimo Corporation | $4,237,000 | -9.6% | 34,020 | -29.2% | 0.15% | -13.5% |
| FOMX | Sell | Foamix Pharmaceuticals Ltd.shares | $4,167,000 | -10.6% | 727,205 | -21.8% | 0.15% | -14.7% |
| CHRS | Sell | Coherus Biosciences, Inc. | $2,472,000 | -26.7% | 149,820 | -37.8% | 0.09% | -29.7% |
| EDIT | Sell | Editas Medicine, Inc. | $2,440,000 | -50.6% | 76,668 | -44.4% | 0.09% | -52.9% |
| EVH | Sell | Evolent Health, Inc. | $2,394,000 | -7.2% | 84,300 | -31.2% | 0.09% | -11.2% |
| NTLA | Sell | Intellia Therapeutics, Inc. | $1,965,000 | -57.1% | 68,671 | -59.0% | 0.07% | -59.2% |
| ACHN | Sell | Achillion Pharmaceuticals, Inc. | $1,710,000 | -1.9% | 464,761 | -24.6% | 0.06% | -6.1% |
| MNKKQ | Sell | Mallinckrodt plcshares | $1,571,000 | +36.0% | 53,600 | -13.4% | 0.06% | +29.5% |
| ARGX | Sell | argenx SEsponsored adr | $1,152,000 | -64.3% | 15,188 | -61.0% | 0.04% | -65.6% |
| AFMD | Sell | Affimed NV | $1,105,000 | -58.8% | 254,000 | -84.4% | 0.04% | -60.8% |
| RMR | Sell | The RMR Group Inc.class a | $494,000 | -15.4% | 5,323 | -28.5% | 0.02% | -18.2% |
| TLGT | Sell | Teligent, Inc. | $401,000 | -87.2% | 101,458 | -88.8% | 0.02% | -87.4% |
| DEPO | Exit | Depomed, Inc. | $0 | – | -62,973 | -100.0% | -0.02% | – |
| NSTG | Exit | NanoString Technologies, Inc. | $0 | – | -74,250 | -100.0% | -0.04% | – |
| TXMD | Exit | TherapeuticsMD, Inc. | $0 | – | -234,384 | -100.0% | -0.06% | – |
| XENE | Exit | Xenon Pharmaceuticals Inc. | $0 | – | -163,819 | -100.0% | -0.06% | – |
| RARX | Exit | Ra Pharmaceuticals, Inc. | $0 | – | -219,952 | -100.0% | -0.08% | – |
| VRX | Exit | Bausch Health Companies Inc. | $0 | – | -192,000 | -100.0% | -0.17% | – |
| WELLPRI | Exit | Welltower Inc.6.50% preferred perpetual | $0 | – | -200,000 | -100.0% | -0.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.